Testing a PSMA-targeted immune drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have castration-resistant prostate cancer (cancer still growing despite hormone therapy) after at least 3 lines of treatment.
- You can understand the study and follow the required visits, treatments, and scans while on the trial.
- Your expected lifespan is more than 3 months.
- You have at least one measurable spot of cancer on CT or MRI that can be checked again later.
- Your general health is good enough (ECOG 0 to 2) to do study activities and appointments.
- Recent blood tests show your bone marrow and organs are working well (enough blood counts, and acceptable liver, kidney, and clotting levels) within 14 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Hear when a new Castration Resistant Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.